by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Cognitive composites offer greater sensitivity to amyloid beta (Aβ)-related decline compared to individual tests for tracking longitudinal cognitive change. We developed and validated data-driven composites from the harmonized Alzheimer’s...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Effective disease-modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION Validation of Alzheimer’s disease blood-based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION Adherence to the Mediterranean–Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet is associated with reduced dementia risk, but underlying mechanisms remain unclear. METHODS Plasma proteomics (SomaScan...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract Alzheimer’s disease (AD) is accompanied by persistent disturbances in brain energy metabolism, and microglial glucose metabolic reprogramming constitutes an important link among pathological protein deposition, neuroinflammation, and impaired clearance....
